Research Paper Volume 16, Issue 1 pp 872—910

XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis

class="figure-viewer-img"

Figure 1. (A) Human XRCC1 gene expression status in various cancers from TCGA database. (B) Wilcoxon signed rank sum test was used to detect the differential expression of XRCC1 in tumor tissues and adjacent paracancerous tissues. (C) The protein expression level of the XRCC1 gene in glioblastoma multiforme, hepatocellular carcinoma, head and neck squamous carcinoma, pancreatic adenocarcinoma, breast cancer, ovarian cancer, colon cancer, lung adenocarcinoma, clear cell RCC. (D) The box plot of tumor pathological stages (stage I, stage II, stage III, stage IV) following ACC, BLCA, LIHC, and clinical stages (stage I, stage II, stage III, stage IV) of HNSC, OSCC. ns P≥0.05, *P<0.05, **P<0.01; ***P<0.001.